Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
| ▸ | CDC42BPB | Q9Y5S2 | 3/20 | 0.40 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5792662 | 0.98 | AR (0.50) | ARALDH1A1LMNAMAPTHTT | |
| SCHEMBL4454407 | 0.87 | AR (0.57) | ARALDH1A1LMNAMAPTHTT | |
| SCHEMBL1331262 | 0.86 | AR (0.56) | ARALDH1A1LMNAMAPTHTT | |
| SCHEMBL16793210 | 0.86 | AR (0.56) | ARALDH1A1LMNAMAPTHTT | |
| SCHEMBL5557765 | 0.85 | ALDH1A1 (0.49) | ALDH1A1HTTROCK2ROCK1CDC42BPB | |
| SCHEMBL16094742 | 0.85 | MAPK1 (0.54) | ALDH1A1LMNAMAPTHTTL3MBTL1 | |
| SCHEMBL26618071 | 0.83 | FFAR4 (0.47) | ARALDH1A1LMNANOS3NOS1 | |
| Hydrochloric Acid SCHEMBL19385661 | 0.83 | ALDH1A1 (0.48) | ALDH1A1LMNAHTTROCK2ROCK1 | |
| SCHEMBL4876309 | 0.82 | AR (0.65) | ARALDH1A1LMNAMAPTHTT | |
| SCHEMBL4871836 | 0.82 | AR (0.65) | ARALDH1A1LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694856-B1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-3694856-B1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| CN-110066278-B | Fused tricyclic compound and application thereof in medicines | 广东东阳光药业有限公司 | 2021-06-08 | — | — | CN | disclosed |
| US-10966970-B2 | Fused tricyclic compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-10966970-B2 | Fused tricyclic compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| EP-3694856-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-08-19 | — | — | EP | disclosed |
| US-20200113879-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-04-16 | — | — | US | disclosed |
| EP-3237396-B1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2019-07-03 | — | — | EP | disclosed |
| WO-2019100735-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019100735-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-05-31 | — | — | WO | disclosed |
| US-9902725-B2 | Heterocyclic derivatives as RORgamma modulators | GENFIT (FR) | 2018-02-27 | — | — | US | disclosed |
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2017-12-07 | — | — | US | disclosed |
| EP-3237396-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | Genfit (FR) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016102633-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2016-06-30 | — | — | WO | disclosed |
| US-20140187556-A1 | ANTI-AMYLOID COMPOUNDS AND METHODS | TREVENTIS CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | RORC, RORB, RORA | AR 937/4885ALDH1A1 976/4885LMNA 3754/4885 |
| US-20140187556-A1 | ANTI-AMYLOID COMPOUNDS AND METHODS | APP, BACE1, PRNP | AR 4798/4885ALDH1A1 4386/4885LMNA 209/4885 |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | AR 4691/4885ALDH1A1 4082/4885LMNA 4842/4885 |
| US-10966970-B2 | Fused tricyclic compounds and uses thereof in medicine | SLC10A1, CYP11B2, CYP11B1 | AR 2274/4885ALDH1A1 1478/4885LMNA 1274/4885 |
| US-20200113879-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SLC10A1, CYP11B2, CYP11B1 | AR 2274/4885ALDH1A1 1478/4885LMNA 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.